Ghent University Academic Bibliography

Journal Article
A1
open access

Dynamics of SARS-CoV-2 IgG in nursing home residents in Belgium throughout three BNT162b2 vaccination rounds : 19-month follow-up

Eline Meyers (UGent) , Liselore De Rop, Claudia Gioveni, Fien Engels, Anja Coen (UGent) , Tine De Burghgraeve, Marina Digregorio, Pauline Van Ngoc, Nele De Clercq, Laetitia Buret, et al.

(2025) VACCINES. 13(4).

Add to list

Journal Article
A1
open access

Exploring TREC and KREC levels in nursing home residents and staff and their association with SARS-CoV-2 antibody response after vaccination

Eline Meyers (UGent) , Natalja Van Biesen (UGent) , Liselore De Rop (UGent) , Tine De Burghgraeve, Marina Digregorio, Laëtitia Buret, Samuel Coenen, Beatrice Scholtes, Jan Y. Verbakel, Stefan Heytens (UGent) , et al.

(2025) VACCINES. 13(8).

Add to list

Journal Article
A1
open access

mRNA galsomes vaccine protects budgerigars against virulent Chlamydia psittaci challenge

Anne De Meyst (UGent) , Joeri Van Mieghem, Koen Chiers (UGent) , Koen Raemdonck (UGent) , Rein Verbeke (UGent) , Ine Lentacker (UGent) and Daisy Vanrompay (UGent)

(2025) VACCINES. 13(2).

Add to list

Journal Article
A1
open access

A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults

Valentino D'Onofrio (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Simon De Gussem (UGent) , Marjolein Verstraete (UGent) , Sharon Porrez (UGent) , Anthony Willems (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Geert Leroux-Roels (UGent) , et al.

(2025) VACCINES. 13(9).

Add to list

Journal Article
A1
open access

Accelerating neoantigen discovery : a high-throughput approach to immunogenic target identification

Lena Pfitzer, Gitta Boons, Lien Lybaert, Wim Van Criekinge (UGent) , Cedric Bogaert and Bruno Fant

(2025) VACCINES. 13(8).

Add to list

Journal Article
A1
open access

Did we overreact? Insights on COVID-19 disease and vaccination in a large cohort of immune-mediated inflammatory disease patients during sequential phases of the pandemic (the BELCOMID study)

Jeroen Geldof (UGent) , Marie Truyens (UGent) , João Sabino, Marc Ferrante, Jo Lambert (UGent) , Hilde Lapeere (UGent) , Tom Hillary, An Van Laethem, Kurt de Vlam, Patrick Verschueren, et al.

(2024) VACCINES. 12(10).

Add to list

Journal Article
A1
open access

PRRSV-vaccinated, seronegative sows and maternally derived antibodies (II) : impact on PRRSV-1 vaccine effectiveness and challenge outcomes in piglets

Jorian Fiers, Dominiek Maes (UGent) , Ann-Brigitte Cay, Frank Vandenbussche, Laurent Mostin, Anna Parys and Marylene Tignon

(2024) VACCINES. 12(3).

Add to list

Journal Article
A1
open access

Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Bart Jacobs, Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Nicola Groth, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Azhar Alhatemi (UGent) , Philippe Moris, et al.

(2024) VACCINES. 12(12).

Add to list

Journal Article
A1
open access

Follow-up of SARS-CoV-2 antibody levels in Belgian nursing home residents and staff two, four and six months after primary course BNT162b2 vaccination

Eline Meyers (UGent) , Liselore De Rop, Fien Engels, Claudia Gioveni, Anja Coen (UGent) , Tine De Burghgraeve, Marina Digregorio, Pauline Van Ngoc, Nele De Clercq (UGent) , Laëtitia Buret, et al.

(2024) VACCINES. 12(8).

Add to list

Journal Article
A1
open access

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Valentino D'Onofrio (UGent) , Sharon Porrez (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Els Michels, Francesca Vanni, Alessandro Manenti, Geert Leroux-Roels (UGent) , et al.

(2024) VACCINES. 12(9).

Academic Bibliography

Dynamics of SARS-CoV-2 IgG in nursing home residents in Belgium throughout three BNT162b2 vaccination rounds : 19-month follow-up

Exploring TREC and KREC levels in nursing home residents and staff and their association with SARS-CoV-2 antibody response after vaccination

mRNA galsomes vaccine protects budgerigars against virulent Chlamydia psittaci challenge

A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults

Accelerating neoantigen discovery : a high-throughput approach to immunogenic target identification

Did we overreact? Insights on COVID-19 disease and vaccination in a large cohort of immune-mediated inflammatory disease patients during sequential phases of the pandemic (the BELCOMID study)

PRRSV-vaccinated, seronegative sows and maternally derived antibodies (II) : impact on PRRSV-1 vaccine effectiveness and challenge outcomes in piglets

Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Follow-up of SARS-CoV-2 antibody levels in Belgian nursing home residents and staff two, four and six months after primary course BNT162b2 vaccination

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Contents

Support

Contact